Table 7. Ongoing clinical trials of first- and second-generation EGFR TKIs in combination with immunotherapy.
| ClinicalTrials.gov identifier | Phase; population | Treatment | Status |
|---|---|---|---|
| NCT01998126 | Phase I; EGFR TKI-naive or not | Nivolumab/ipilimumab + erlotinib | Ongoing, not recruiting |
| NCT01454102 | Phase I; EGFR TKI-naive or not; CheckMate 012 | Nivolumab + erlotinib (arm E) | Ongoing, not recruiting |
| NCT02574078 | Phase I/II; EGFR TKI-naive or not (maintenance) | Nivolumab + erlotinib | Ongoing, not recruiting |
| NCT02039674 | A Phase I/II; EGFR TKI-naive | Pembrolizumab + erlotinib (cohort E); pembrolizumab + gefitinib (cohort F) | Ongoing, not recruiting |
| NCT02364609 | Phase I; erlotinib-resistant | Pembrolizumab + afatinib | Recruiting |
| NCT03157089 | Phase II; squamous cell lung cancer; 3rd-line and more; (LUX-Lung IO) | Pembrolizumab + afatinib | Recruiting |
| NCT02013219 | Phase I; EGFR TKI-naive | Atezolizumab + erlotinib | Ongoing, not recruiting |
| NCT02088112 | Phase I; EGFR TKI-naive or not | Durvalumab + gefitinib | Ongoing, not recruiting |
| NCT01998126 | Phase I; EGFR TKI-naive or not | Ipilimumab + erlotinib | Ongoing, not recruiting |
| NCT02040064 | Phase I; EGFR TKI-pretreated; GEFTREM | Tremelimumab + gefitinib | Ongoing, not recruiting |
| NCT02906163 | Phase I/II; EGFR TKI-naive | Afatinib, gefitinib, erlotinib + thymosin alpha 1 (a peptide immune modulator) (phase II) vs. afatinib, gefitinib, erlotinib | Ongoing, not recruiting |
EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.